Across TCGA pan-cancer cohorts, RPL39P16 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated RPL39P16 data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RPL39P16 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL39P16 expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.
KIRC, READ, and LIHC are the cancer types where RPL39P16 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.